AI Assistant
Blog
Pricing
Log In
Sign Up
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
